Drug intelligence / Profile preview

Ready Medical Post Treatment

Development stage: Phase 3
Lead developer: Ready Medical
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Ready Medical Post Treatment is a wound healing product consisting of a combination of hyaluronic acid (50 kDa), perfluorodecalin, and physalis angulata extract. This formulation is designed to promote faster healing and reduce scar formation in wounds. Clinical studies have shown it significantly improves wound closure rates and reduces exuding areas compared to standard dressings.

Brand names: Ready Medical Post Treatment
Other names: Ready Medical HA + Perfluorodecalin + Physalis AngulataReady Medical Healing

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on Ready Medical Post Treatment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ready Medical Post Treatment.

Explore the full profile